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Abstract
Objective—To reduce dosing errors when administering orally-ingested over-the-counter (OTC) 
liquid medications, the US Food and Drug Administration (FDA) and the Consumer Healthcare 
Products Association (CHPA) released voluntary recommendations for dosing directions and 
dosing devices. This study assessed recommendation adherence for national brand-name orally-
ingested OTC liquid pediatric analgesics/antipyretics and cough, cold, and allergy medications 
available after the FDA Guidance was finalized in 2011 in order to identify and prioritize specific 
improvements to dosing directions and dosing devices.
Methods—Recommendations were categorized as top tier or low tier based on potential to 
directly address ≥3-fold dosing errors. Labeled dosing directions and accompanying dosing 
devices were assessed by 2 independent reviewers for adherence to specific recommendations.
Results—Of 68 products, 91% of dosing directions and 62% of dosing devices adhered to all top 
tier recommendations; 57% of products adhered to every top tier recommendation and 93% 
adhered to all or all but one. A dosing was included with all products. No dosing directions used 
atypical volumetric units (e.g., drams), and no devices used volumetric units that did not appear in 
dosing directions. Six products used trailing zeros or failed to use leading zeros with decimal 
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doses and 8 did not use small font for fractions. Product adherence to low tier recommendations 
ranged from 26% to 91%.
Conclusion—Products adhered to most recommendations in the final FDA Guidance and CHPA 
Guideline suggesting that these voluntary initiatives promote adherence to recommendations. 
Improving adherence to recommendations should be prioritized based on potential to reduce harm.
Keywords
dosing error; unintentional overdose; medication label; dosing device; over-the-counter medicines
In response to reports of unintentional overdoses of orally-ingested over-the-counter (OTC) 
liquid medications due to dosing devices with markings that were inconsistent or 
incompatible with labeled dosing directions, the US Food and Drug Administration (FDA) 
released a draft guidance for industry.1 This voluntary guidance, “Dosage Delivery Devices 
for Orally Ingested OTC Liquid Drug Products” (hereafter “FDA Guidance”), finalized in 
May 2011, outlines specific recommendations for aligning dosing devices with the 
accompanying dosing directions for orally-ingested OTC liquid medications.2 Since many 
OTC liquid medications are intended for pediatric use, minimizing potential errors during 
dose measurement and administration by caregivers is a key focus of the guidance.
In 2009, concurrent to the initial draft FDA Guidance, the Consumer Healthcare Products 
Association (CHPA), a trade organization representing OTC medication manufacturers, 
released a voluntary guideline, “Volumetric Measures for Dosing of Over-the-Counter Oral 
Liquid Drug Products for Children ≤12 years of Age” (hereafter “CHPA Guideline”), to 
standardize volumetric measures used in dosing directions as well as devices.3 The 
following year, using a sample of “baseline” products, Yin et al reported the concerning 
finding that 98.6% of evaluated OTC liquid medications had “inconsistencies” between 
dosing directions and device markings.4
We assessed adherence to recommendations in the final FDA Guidance and CHPA 
Guideline in a sample of national brand-name orally-ingested OTC liquid medications with 
pediatric dosing available on the market after the final FDA Guidance was released. To 
prioritize areas for improvement in labeled dosing directions and accompanying devices, 




In December 2011, CHPA member manufacturers were asked to submit sample products for 
all currently available orally-ingested OTC liquid medications with specified dosing for 
children <12 years of age. National brand-name analgesics/antipyretics and cough, cold, and 
allergy products (e.g., PediaCare®, Robitussin®) were included in the study; generic 
products, including those branded for specific retailers (e.g., Walgreens®, Wal-Mart®) were 
not included. Market share of individual brands within each drug class was determined using 
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SymphonyIRI InfoScan Tracking data on units sold to consumers from food, drug, and mass 
(FDM) merchandisers (excluding Wal-Mart) for the 1-year period ending January 22, 2012.
Definitions
Drug classification (analgesics/antipyretics or cough, cold, and allergy products) was based 
on labeled indications. Medications were categorized as infants’, children’s, or family 
products based on the age group indicated on the front panel of the outer packaging (i.e., the 
outer box or medication bottle), since such visual cues are used by consumers when deciding 
which medication to purchase.5 Within each brand, unique products were identified based 
on the product trade name and targeted age group. If products were available in multiple 
flavors, bottle sizes, or dye-free versions, one version (e.g., a single flavor) was randomly 
selected, so that each unique product would be given equal weight.
Standard abbreviations for volumetric units were identified by recommended or customary 
use. The FDA Guidance, CHPA Guideline, US Pharmacopeial Convention, the Institute for 
Safe Medication Practices, and others specify that milliliters should be abbreviated as 
“mL”.2,3,6,7 The FDA Guidance and CHPA Guideline specify that teaspoon should be 
abbreviated as “tsp”, but as there is no uniformly recommended abbreviation for tablespoon 
units, “TBSP” was considered the standard abbreviation based on common use.8 
Pluralization of abbreviations is not addressed by the FDA Guidance or CHPA Guideline 
and was considered acceptable.
Outcomes
Adherence to specific recommendations in the final FDA Guidance and CHPA Guideline 
was assessed (Figure 1). Recommendations were categorized as “top tier” or “low tier” by 
the authors based on potential for reducing clinically meaningful dosing errors 
(Supplemental Appendix). Top tier recommendations directly address potential dosing 
errors of 3-fold or more. For example, use of trailing zeros in the dosing directions can lead 
to 10-fold overdoses if the decimal point is overlooked (i.e., a labeled dose of 1.0 mL is 
mistaken for 10 mL).6,7,9–12 Low tier recommendations improve consistency and maintain 
conventional standards of abbreviation and capitalization, but do not directly address ≥3-
fold dosing errors. For example, milliliters should always be abbreviated “mL” (i.e., not 
“ml” or “ML”).2,3,6,7
The recommendation that dosing devices should not be significantly larger than the largest 
dose in the dosing directions does not quantify “significantly larger.” For this study a dosing 
device with total volume ≥3-times the largest labeled dose was considered significantly 
larger. Two other recommendations without objective parameters (device markings should 
be “clearly visible” after product is added and devices should allow “clear measurement” of 
the smallest intended dose) were not assessed.
Data collection and analysis
Products were evaluated independently by two investigators (MCL and KOR). A third 
reviewer (DSB) resolved discordant assessments. Adherence to recommendations was 
assessed by reviewing dosing directions on bottle labels and attributes of the accompanying 
Budnitz et al. Page 3













dosing devices. Dosing directions on the outer boxes and other written materials were not 
reviewed since some products are packaged only in the immediate container (i.e., 
medication bottle) and outer packaging and other written materials may be discarded after 
purchase. Adherence to recommendations was tabulated and analyzed using SAS version 9.2 
(SAS Institute, Cary, NC). Product-specific findings were shared with respective 
manufacturers.
Results
A total of 89 national brand-name analgesic/antipyretic and cough, cold, and allergy 
products were collected from January – April 2012. Of these, 68 products representing 21 
brands from 12 manufacturers were included in the final analysis. Four products did not 
meet study inclusion criteria and 17 were identical to an included product except for flavor, 
bottle size, or use of dye. The final sample included 100% of analgesic/antipyretic national 
brands and 98.6% of cough, cold, and allergy product national brands available during the 
study period based on units sold from FDM stores. Of the 68 products, 81% were cough, 
cold, and allergy medications and 88% were marketed as infants’ or children’s products 
(Table 1). Of the 55 cough, cold, and allergy medications, 9 (16%) were homeopathic 
products. A dosing device was provided with all products, most often a dosing cup (85%); 
all infants’ products were analgesics/antipyretics packaged with oral syringes. Across the 68 
products, agreement between the two reviewers on adherence to 22 specific top tier and low 
tier recommendations was high; only 8 of 1,496 independent assessments required 
resolution by a third reviewer.
Ninety-one percent (62/68) of dosing directions and 62% (42/68) of devices adhered to all 
top tier recommendations. Over half of products (57%; 39/68) adhered to all top tier 
recommendations for both dosing directions and devices, and 93% (63/68) adhered to all or 
all but one top tier recommendation. Milliliters, teaspoons, and tablespoons were the only 
volumetric units used; atypical units, such as drams or dropperfuls, were never used (Table 
2). All products avoided using teaspoon and tablespoon units together on devices; however, 
2 products used both units in the dosing directions.
Most products adhered to recommendations specifying how numeric doses should be 
expressed. Where applicable, leading zeros were used and trailing zeros were omitted on 
88% (15/17) of dosing directions and 85% (34/40) of devices. The 6 devices that used 
trailing zeros or failed to use leading zeros were oral syringes or droppers. Smaller font was 
used for fractional doses (e.g., “½”) on 80% (8/10) of dosing directions and 74% (20/27) of 
devices. All devices that did not use smaller font for fractions were dosing cups.
No dosing devices used extraneous units; all 68 dosing devices only used volumetric units 
that were specified in the dosing directions. Twelve children’s products included dosing 
cups with total volumes that were ≥3-times larger than the largest dose in the directions; the 
12 cups averaged 3.4-times larger than the largest labeled dose (range 3.3 – 3.8-times 
larger). All doses from the dosing directions were explicitly marked on devices for all but 4 
products (94%; 64/68); these 4 products included devices (2 droppers and 2 syringes) that 
needed to be filled >1 time to measure labeled doses.
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Adherence to low tier recommendations varied (Table 3). Most products used standard 
abbreviations in the dosing directions (91%; 59/65) and on devices (72%; 49/68); all 
nonstandard abbreviations only differed in capitalization. Of 19 products that used non-
standard abbreviations, 14 used “ml” and 2 used “ML” for milliliters (instead of “mL”) and 
3 used “TSP” for teaspoons (instead of “tsp”). Of 65 products that used abbreviations for 
volumetric units both in dosing directions and on devices, 80% used exactly the same 
abbreviation in both locations. Again, all differences were related to capitalization (e.g., use 
of “mL” in dosing directions and “ml” on the device).
Few devices (28%; 19/68) only had the numeric markings for doses specified in the 
directions (e.g., directions specify doses of 5 mL or 10 mL; accompanying device only has 5 
mL and 10 mL markings); Most devices had multipurpose numeric dosing scales (e.g., 2.5 
mL increments starting with 5 mL and ending with 20 mL). Seventy-two percent of products 
(49/68) included a statement to only use the enclosed device with the product, used a 
physical mechanism (e.g., dosing cup that attaches to bottle cap) to link devices with 
accompanying products, or had both. The 6 cough, cold, and allergy products with dosing 
directions that used tablespoon units, in addition to other units, included a statement that 
doses could be measured using the device provided or a spoon.
The volumetric units used on the dosing devices were exactly the same as the units used in 
the directions for 90% of products (61/68) (Table 4). Dosing directions on 7 other products 
included additional volumetric units not found on accompanying devices. Of the 68 
products, 19 dosing directions (28%) and 25 devices (37%) followed the CHPA Guideline’s 
primary preference to use only milliliter units. Alternatively, the CHPA Guideline 
recommends using milliliters in combination with teaspoon units; 74% of products (50/68) 
used milliliters alone or in combination with teaspoons. A dosing chart was used to specify 
doses in the dosing directions on 76% of products.
Discussion
This study is the first to assess dosing directions and dosing devices in a sample of products 
available after the voluntary FDA Guidance was finalized in 2011. Among 68 national 
brand-name orally-ingested OTC liquid medications, 91% of dosing directions and 62% of 
included devices adhered to all recommendations that directly address ≥3-fold dosing errors 
(top tier recommendations). Adherence to individual recommendations intended to improve 
the clarity and consistency of labeled doses and accompanying devices (low tier 
recommendations) ranged from 26% to 91%. Specific findings help identify areas for 
product improvement and recommendation refinement.
In this sample of 68 products, there was 100% adherence to several key recommendations 
which address issues that have been directly implicated in clinically significant errors. All 
68 products included dosing devices to discourage use of household spoons or other non-
calibrated devices.13,14 No dosing directions or devices used atypical volumetric units (e.g., 
drams, milligrams, or dropperfuls) and no devices had extraneous units that did not appear 
in the dosing directions.15,16 Two products mixed teaspoon and tablespoon units in the 
dosing directions (a cause of 3-fold errors),17,18 but both have since been discontinued.
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There is opportunity to improve the expression of decimals and fractions. Most non-
adherence to these recommendations occurred with dosing devices, but for overdose 
prevention, non-adherence in dosing directions is most critical. Two products used trailing 
zeros in the directions, which could lead to 10-fold overdosing errors (e.g., interpreting 
“1.0” as “10”).6,7,9–12 One product did not use leading zeros and five products used trailing 
zeros on dosing devices; however, overlooking decimal points on devices would likely lead 
to underdosing. Expressing fractional doses with small font has been suggested as a means 
to prevent errors from misinterpreting “1/2” as “1 or 2” (i.e., a potential 4-fold error) or 
overlooking the fraction bar altogether.9 Small font was not used for fractional doses in 2 
dosing directions (potential for overdose) and on 7 devices (potential for underdose).
Two recommendations related to device size required interpretation to assess adherence. 
First, to limit the magnitude of overdoses from patients or caregivers assuming that a full 
device holds “one dose” or “one unit”,18 dosing devices should not be “significantly larger” 
than doses specified in the directions. Twelve devices were slightly larger than the 3-fold 
cutoff (3.3 - 3.8-times larger) used to define “significantly larger” in this study. Second, to 
prevent situations in which doses specified in the directions cannot be measured using the 
device provided,15,16 devices should include markings that can measure all labeled doses. 
We considered 4 products that needed to be filled >1 time to measure the largest dose to be 
non-adherent. Updated guidelines could define when larger devices are “significantly larger” 
than needed and clarify whether or not smaller devices that may need to be filled more than 
once are recommended.
Eliminating extraneous markings on devices is recommended to reduce potential for 
confusion, but some exceptions may be well-intentioned and this recommendation surpasses 
current practice for prescription products. Only 28% of devices assessed in this study 
included just the numeric doses specified in dosing directions, typically because the device 
had a general numeric scale. However, additional numeric dose markings on devices may be 
useful for accommodating professional dosing recommendations to use smaller doses than 
the labeled directions.2 It is notable that when devices are provided with prescription 
medications (and sometimes patients must explicitly request them) the large majority are not 
tailored to the prescription but are “off-the-shelf” devices that have general numeric scales 
and may have multiple volumetric units to accommodate numerous doses and units.19
One recommendation with <50% adherence is to link medications and accompanying 
devices. One rationale is that devices are calibrated to account for product viscosity and 
other factors; however, such fine measurement accuracy is unlikely to cause clinically 
significant overdoses of OTC products. Another rationale is to discourage use of household 
spoons which can vary considerably in fill capacity.14,20,21 The dosing directions for 6 
products stated that the included dosing cup or a teaspoon and/or tablespoon could be used. 
While 2 of these products have been discontinued, the remaining products’ directions should 
not suggest use of household spoons.
Three low tier recommendations focus on capitalization conventions and definition of 
abbreviations. Capitalization differences (e.g., “ml” instead of “mL”) accounted for all 
instances of non-adherence to the recommendations to use standard abbreviations for 
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volumetric units and to ensure device abbreviations match dosing direction abbreviations. 
While abbreviations should generally be defined, definitions for common abbreviations may 
not be necessary,22 particularly when the same abbreviation is used both in the dosing 
directions and on the device. Fifty-six products used milliliters both in the directions and on 
devices; all 56 used an abbreviation in both locations. In this situation, it is unclear if 
defining the abbreviation aids in error prevention.
Using milliliters (expressed as mL), as the primary volumetric unit could address many 
guidance/guideline goals. An “mL only” approach discourages use of household spoons, 
avoids confusion between teaspoons and tablespoons, and limits confusion from use of 
multiple units. Milliliters are the standard units for dosing orally-ingested liquid medications 
in inpatient settings,6,11,23 and there is increasing consensus that use of milliliters for dosing 
orally-ingested liquid medications is preferred for outpatient settings as well.24–27 Nearly 
three-fourths of products in this study (74%) followed CHPA’s recommendation to use 
milliliters alone or in combination with teaspoon units, and success in adopting milliliters on 
OTC products has facilitated efforts to encourage use of milliliters on prescription product 
labels.28–30 Nonetheless, ongoing monitoring would be appropriate to identify unintended 
consequences of milliliter-only dosing.
The manner in which results are reported can substantially impact interpretation of findings. 
A previous study by Yin et al evaluated a sample of products available prior to release of the 
draft FDA Guidance and concluded that 98.6% had at least one “inconsistency.”4 However, 
aggregating inconsistencies by combining serious issues (e.g., representation of decimal 
doses) with less serious issues (e.g., inconsistent capitalization for milliliter abbreviations) 
and giving equal weight to serious and less serious issues could lead to over-statement of 
problems. In addition, reporting measures of inconsistency that combine issues with the 
dosing directions and issues with dosing devices clouds rather than clarifies where dosing 
directions improvements are needed and where devices improvements are needed. While 
differences in study design and inclusion criteria do not allow direct comparisons, findings 
from this study suggest that, overall, products collected after the CHPA Guideline and final 
FDA Guidance adhered to most recommendations, particularly those addressing clinically 
meaningful errors. After analyses were completed for this study, product-specific findings 
were shared with respective manufacturers and several label and device updates have been 
made.
Study findings are subject to several limitations. This study assessed national brand-name 
analgesic/antipyretic and cough, cold, and allergy medications with pediatric dosing 
available on the market during the study period. Findings may not be generalizable to 
national brand-name products that were not available during the study period (e.g., due to 
product recalls) or to generic products. Adherence of generic products available after the 
final FDA Guidance should be assessed. Findings also may not be generalizable to other 
OTC drug classes, but analgesic/antipyretic and cough, cold, and allergy medications are the 
OTC medications involved in most emergency visits for therapeutic errors involving 
children ≤5 years of age.31 Products were collected through a request sent to CHPA member 
manufacturers, and possibly eligible products from non-member manufacturers were not 
included. However, the products evaluated represented over 98% of units of national brand-
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name products in the included drug classes sold during the study period. Lastly, we did not 
evaluate other product characteristics such as use of concentration (mg/mL) or pictures or 
graphics on product packaging.
Conclusion
Findings suggest that these voluntary initiatives promote adherence to label and device 
recommendations. Further improving adherence to top tier recommendations addressing 
potential for ≥3-fold errors should be prioritized, but detailed reporting by patients and care 
providers is needed to identify the specific ways packaging and dose devices contribute to 
errors. Additional opportunities for standardization include design and marking of dosing 
devices and promotion of milliliter as the standard unit for dosing orally-ingested liquid 
medications. Evaluation and continued improvement of labels and devices for OTC liquid 
medications should be ongoing and transparent as new products are introduced and 
recommendations are revised.
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Refer to Web version on PubMed Central for supplementary material.
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What’s Known on This Subject
Due to reports of unintentional overdoses, in 2011 the US Food and Drug Administration 
finalized voluntary recommendations for dosing devices included with orally-ingested 
over-the-counter (OTC) medications. The Consumer Healthcare Products Association 
previously endorsed similar recommendations for devices and dosing directions.
What This Study Adds
This study assessed dosing directions and devices for national brand-name OTC liquid 
medications, available after a voluntary FDA guidance, and found high levels of 
adherence to most recommendations. Further improvement efforts should prioritize 
recommendations that directly address potential dosing errors.
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Recommendations from the 2011 FDA Voluntary Guidance and 2009 CHPA Voluntary 
Guideline
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TABLE 1
Characteristics of Orally-ingested OTC Liquid Products Assessed for Adherence to Recommendations from 
the 2011 FDA Voluntary Guidance and 2009 CHPA Voluntary Guideline
Characteristic n %
Drug Class
  Analgesic/antipyretic 13 19
  Cough, cold, and allergy 55 81
Age Category
  Infants 5 7
  Children 55 81
  Family 8 12
Device Type
  Printed cup 38 56
  Etched cup 20 29
  Oral syringe 6 9
  Dosing spoon 2 3
  Dropper 2 3
Total 68 100
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